Evaluation of prognostic factors for survival in patients with Hepatocellular carcinoma treated with Transarterial Chemoembolisation

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and the second leading cause of cancer related mortality globally. This is due to the majority of patients presenting at a disease stage not amenable to curative treatments. Transarterial Chemoembolisation (TACE) is the most common treatment for patients with unresectable HCC, however the median survival ranges from 20 to 45 months. Through collaboration with six large Australian tertiary centres and international co-authors this thesis undertakes a comprehensive evaluation of the prognostic factors associated with survival in patients with unresectable HCC undergoing treatment with TACE.